Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.24
COV's Cash to Debt is ranked higher than
53% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. COV: 0.24 )
COV' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 0.24

Equity to Asset 0.49
COV's Equity to Asset is ranked higher than
61% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. COV: 0.49 )
COV' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.61
Current: 0.49

0.36
0.61
Interest Coverage 10.25
COV's Interest Coverage is ranked higher than
61% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. COV: 10.25 )
COV' s 10-Year Interest Coverage Range
Min: 2.33   Max: 66.5
Current: 10.25

2.33
66.5
F-Score: 6
Z-Score: 3.36
M-Score: -2.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 20.83
COV's Operating margin (%) is ranked higher than
91% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. COV: 20.83 )
COV' s 10-Year Operating margin (%) Range
Min: 4.31   Max: 26.05
Current: 20.83

4.31
26.05
Net-margin (%) 16.61
COV's Net-margin (%) is ranked higher than
90% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.98 vs. COV: 16.61 )
COV' s 10-Year Net-margin (%) Range
Min: -3.26   Max: 17.95
Current: 16.61

-3.26
17.95
ROE (%) 18.39
COV's ROE (%) is ranked higher than
92% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. COV: 18.39 )
COV' s 10-Year ROE (%) Range
Min: -4.92   Max: 23.53
Current: 18.39

-4.92
23.53
ROA (%) 8.53
COV's ROA (%) is ranked higher than
86% of the 299 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. COV: 8.53 )
COV' s 10-Year ROA (%) Range
Min: -1.81   Max: 9.26
Current: 8.53

-1.81
9.26
ROC (Joel Greenblatt) (%) 63.02
COV's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. COV: 63.02 )
COV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.67   Max: 63.02
Current: 63.02

9.67
63.02
Revenue Growth (%) 1.60
COV's Revenue Growth (%) is ranked higher than
69% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. COV: 1.60 )
COV' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 9.2
Current: 1.6

0
9.2
EBITDA Growth (%) 5.60
COV's EBITDA Growth (%) is ranked higher than
70% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.40 vs. COV: 5.60 )
COV' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 50.9
Current: 5.6

0
50.9
EPS Growth (%) 3.10
COV's EPS Growth (%) is ranked higher than
71% of the 242 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. COV: 3.10 )
COV' s 10-Year EPS Growth (%) Range
Min: 0   Max: 21.9
Current: 3.1

0
21.9
» COV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

COV Guru Trades in Q3 2013

Jim Simons 6,900 sh (New)
Manning & Napier Advisors, Inc 85,940 sh (New)
Robert Olstein 91,000 sh (+40%)
Jeremy Grantham 564,305 sh (+18.98%)
Mario Gabelli 612,839 sh (+7.31%)
John Keeley 94,050 sh (+3.65%)
Bill Nygren 2,708,000 sh (+3.04%)
Ronald Muhlenkamp 174,620 sh (+0.26%)
HOTCHKIS & WILEY 1,234,722 sh (+0.17%)
Private Capital 385,574 sh (+0.1%)
Steven Romick 4,851,700 sh (unchged)
Yacktman Fund 850,000 sh (unchged)
First Pacific Advisors 5,386,500 sh (unchged)
Jean-Marie Eveillard 1,500 sh (unchged)
Yacktman Focused Fund 800,000 sh (unchged)
Vanguard Health Care Fund 4,002,600 sh (unchged)
Donald Yacktman 1,795,975 sh (-0.56%)
Dodge & Cox 111,317 sh (-0.62%)
Pioneer Investments 2,989,306 sh (-7.65%)
Joel Greenblatt 16,584 sh (-64.08%)
Steven Cohen 22,057 sh (-94.41%)
» More
Q4 2013

COV Guru Trades in Q4 2013

Ray Dalio 80,858 sh (New)
Jeremy Grantham 1,224,091 sh (+116.92%)
Steven Cohen 32,119 sh (+45.62%)
Vanguard Health Care Fund 4,994,700 sh (+24.79%)
Ronald Muhlenkamp 181,635 sh (+4.02%)
Robert Olstein 94,500 sh (+3.85%)
Mario Gabelli 622,152 sh (+1.52%)
Pioneer Investments 3,017,822 sh (+0.95%)
Yacktman Focused Fund 800,000 sh (unchged)
Bill Nygren 2,708,000 sh (unchged)
Jean-Marie Eveillard 1,500 sh (unchged)
Dodge & Cox 111,317 sh (unchged)
Steven Romick 4,851,700 sh (unchged)
Yacktman Fund 850,000 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Donald Yacktman 1,790,375 sh (-0.31%)
First Pacific Advisors 5,346,800 sh (-0.74%)
Manning & Napier Advisors, Inc 80,770 sh (-6.02%)
Private Capital 244,555 sh (-36.57%)
HOTCHKIS & WILEY 657,000 sh (-46.79%)
John Keeley 44,520 sh (-52.66%)
» More
Q1 2014

COV Guru Trades in Q1 2014

Louis Moore Bacon 6,022 sh (New)
Joel Greenblatt 3,746 sh (New)
Paul Tudor Jones 289,467 sh (New)
Jeremy Grantham 2,103,588 sh (+71.85%)
HOTCHKIS & WILEY 788,400 sh (+20%)
Pioneer Investments 3,131,476 sh (+3.77%)
Yacktman Focused Fund 800,000 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Bill Nygren 2,708,000 sh (unchged)
Yacktman Fund 850,000 sh (unchged)
Jean-Marie Eveillard 1,500 sh (unchged)
Robert Olstein 94,500 sh (unchged)
Steven Romick 4,851,700 sh (unchged)
Ronald Muhlenkamp 181,455 sh (-0.1%)
Private Capital 243,820 sh (-0.3%)
Donald Yacktman 1,784,825 sh (-0.31%)
John Keeley 43,770 sh (-1.68%)
First Pacific Advisors 5,184,500 sh (-3.04%)
Dodge & Cox 101,517 sh (-8.8%)
Manning & Napier Advisors, Inc 71,870 sh (-11.02%)
Mario Gabelli 543,560 sh (-12.63%)
Ray Dalio 47,058 sh (-41.8%)
Steven Cohen 6,418 sh (-80.02%)
» More
Q2 2014

COV Guru Trades in Q2 2014

John Paulson 7,000,000 sh (New)
Eric Mindich 446,000 sh (New)
George Soros 227,000 sh (New)
Louis Moore Bacon 126,022 sh (+1992.69%)
Jeremy Grantham 2,776,488 sh (+31.99%)
Mario Gabelli 637,530 sh (+17.29%)
Ronald Muhlenkamp 182,180 sh (+0.4%)
HOTCHKIS & WILEY 788,700 sh (+0.04%)
Jean-Marie Eveillard 1,500 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Robert Olstein Sold Out
Yacktman Fund Sold Out
Manning & Napier Advisors, Inc Sold Out
Donald Yacktman Sold Out
Yacktman Focused Fund Sold Out
Private Capital 238,715 sh (-2.09%)
Steven Romick 4,559,929 sh (-6.01%)
John Keeley 40,840 sh (-6.69%)
First Pacific Advisors 4,822,800 sh (-6.98%)
Dodge & Cox 92,017 sh (-9.36%)
Pioneer Investments 1,818,973 sh (-41.91%)
Bill Nygren 160,000 sh (-94.09%)
Paul Tudor Jones 7,416 sh (-97.44%)
» More
» Details

Insider Trades

Latest Guru Trades with COV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-06-30 New Buy2.7%$69.03 - $91.24 $ 87.0817%7000000
Yacktman Focused Fund 2014-06-30 Sold Out 0.62%$69.03 - $91.24 $ 87.0817%0
Yacktman Fund 2014-06-30 Sold Out 0.56%$69.03 - $91.24 $ 87.0817%0
Donald Yacktman 2014-06-30 Sold Out 0.55%$69.03 - $91.24 $ 87.0817%0
George Soros 2014-06-30 New Buy0.15%$69.03 - $91.24 $ 87.0817%227000
Ray Dalio 2014-06-30 Sold Out 0.03%$69.03 - $91.24 $ 87.0817%0
Joel Greenblatt 2014-06-30 Sold Out $69.03 - $91.24 $ 87.0817%0
Ray Dalio 2014-03-31 Reduce -41.8%0.02%$66.35 - $72.5 $ 87.0825%47058
Joel Greenblatt 2014-03-31 New Buy$66.35 - $72.5 $ 87.0825%3746
Vanguard Health Care Fund 2013-12-31 Add 24.79%0.22%$59.82 - $68.42 $ 87.0834%4994700
John Keeley 2013-12-31 Reduce -52.66%0.06%$59.82 - $68.42 $ 87.0834%44520
Ray Dalio 2013-12-31 New Buy0.04%$59.82 - $68.42 $ 87.0834%80858
Joel Greenblatt 2013-12-31 Sold Out 0.03%$59.82 - $68.42 $ 87.0834%0
Joel Greenblatt 2013-09-30 Reduce -64.08%0.08%$57.12 - $63.8 $ 87.0843%16584
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Covidien PLC

Steven Romick's Top Five Stocks
Steven Romick is the portfolio manager of First Pacific Advisors Crescent Fund. The fund’s investment objective and strategy reports that they “seek to generate equity-like returns over the long-term, take less risk than the market and avoid permanent impairment of capital.” Read more...
Weekly CFO Sells Highlight: Chicago Bridge and Iron Company, Covidien PLC, Carnival PLC, Google Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Chicago Bridge and Iron Company, Covidien PLC, Carnival PLC, and Google Inc. Read more...
Weekly 52-Week Highs Highlight: COV, EQT, XLNX, TEVA
According to GuruFocus list of 52-week highs, Covidien PLC, EQT Corp, Xilinx Inc. and Teva Pharmaceuticals Industries Ltd. have all reached their 52 week highs. Read more...
‘Kids & Money’ Ron Muhlenkamp, 11 Sells
Guru Ronald Muhlenkamp’s company has a unique differentiator: a special interest in teaching kids about money. Muhlenkamp & Company is the only known investment firm that posts lessons online to help parents teach their children the basics of investing. According to the company’s far-reaching wisdom, “Probably the best time to teach children about money is when they begin to observe habits of spending, savings, investing, and budgeting. Without good mentoring, it is natural for children to assume that money is simply available at the nearest ATM or by handing over your credit card to the cashier.” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.30
COV's P/E(ttm) is ranked higher than
80% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.60 vs. COV: 26.30 )
COV' s 10-Year P/E(ttm) Range
Min: 10.07   Max: 27.68
Current: 26.3

10.07
27.68
P/B 4.00
COV's P/B is ranked higher than
54% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. COV: 4.00 )
COV' s 10-Year P/B Range
Min: 1.64   Max: 4.16
Current: 4

1.64
4.16
P/S 3.79
COV's P/S is ranked higher than
52% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. COV: 3.79 )
COV' s 10-Year P/S Range
Min: 1.25   Max: 4
Current: 3.79

1.25
4
PFCF 25.50
COV's PFCF is ranked higher than
84% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.20 vs. COV: 25.50 )
COV' s 10-Year PFCF Range
Min: 9.51   Max: 213.27
Current: 25.5

9.51
213.27
EV-to-EBIT 22.18
COV's EV-to-EBIT is ranked higher than
78% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. COV: 22.18 )
COV' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 89.9
Current: 22.18

6.8
89.9
PEG 3.96
COV's PEG is ranked higher than
85% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. COV: 3.96 )
COV' s 10-Year PEG Range
Min: 0.38   Max: 4.79
Current: 3.96

0.38
4.79
Shiller P/E 25.60
COV's Shiller P/E is ranked higher than
86% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. COV: 25.60 )
COV' s 10-Year Shiller P/E Range
Min: 17.65   Max: 26.83
Current: 25.6

17.65
26.83
Current Ratio 1.81
COV's Current Ratio is ranked higher than
62% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. COV: 1.81 )
COV' s 10-Year Current Ratio Range
Min: 0.89   Max: 2.85
Current: 1.81

0.89
2.85
Quick Ratio 1.30
COV's Quick Ratio is ranked higher than
63% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. COV: 1.30 )
COV' s 10-Year Quick Ratio Range
Min: 0.73   Max: 2.17
Current: 1.3

0.73
2.17

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.47
COV's Dividend Yield is ranked higher than
59% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. COV: 1.47 )
COV' s 10-Year Dividend Yield Range
Min: 0.41   Max: 2.51
Current: 1.47

0.41
2.51
Dividend Payout 0.37
COV's Dividend Payout is ranked higher than
81% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. COV: 0.37 )
COV' s 10-Year Dividend Payout Range
Min: 0.19   Max: 1.43
Current: 0.37

0.19
1.43
Dividend growth (3y) 12.00
COV's Dividend growth (3y) is ranked higher than
84% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.00 vs. COV: 12.00 )
COV' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 66.6
Current: 12

0
66.6
Yield on cost (5-Year) 2.61
COV's Yield on cost (5-Year) is ranked higher than
74% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.41 vs. COV: 2.61 )
COV' s 10-Year Yield on cost (5-Year) Range
Min: 0.71   Max: 4.36
Current: 2.61

0.71
4.36
Share Buyback Rate 2.20
COV's Share Buyback Rate is ranked higher than
93% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.20 vs. COV: 2.20 )
COV' s 10-Year Share Buyback Rate Range
Min: 0   Max: -0.5
Current: 2.2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.70
COV's Price/DCF (Projected) is ranked higher than
84% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.22 vs. COV: 1.70 )
COV' s 10-Year Price/DCF (Projected) Range
Min: 1.07   Max: 1.76
Current: 1.7

1.07
1.76
Price/Median PS Value 1.80
COV's Price/Median PS Value is ranked higher than
58% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. COV: 1.80 )
COV' s 10-Year Price/Median PS Value Range
Min: 0.72   Max: 1.91
Current: 1.8

0.72
1.91
Price/Peter Lynch Fair Value 4.50
COV's Price/Peter Lynch Fair Value is ranked higher than
86% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. COV: 4.50 )
COV' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.42   Max: 4.72
Current: 4.5

0.42
4.72
Earnings Yield (Greenblatt) 4.50
COV's Earnings Yield (Greenblatt) is ranked higher than
65% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. COV: 4.50 )
COV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 14.8
Current: 4.5

1.1
14.8
Forward Rate of Return (Yacktman) 9.03
COV's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.14 vs. COV: 9.03 )
COV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.5   Max: 37
Current: 9.03

9.5
37

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, TMO, COO, ISRG » details
Traded in other countries:6COP.Germany
Covidien plc formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. The Company operates its business through four segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, soft tissue repair products, energy devices, oximetry and monitoring products, airway and ventilation products, vascular devices, SharpSafety products, clinical care products and other medical device products; Imaging Solutions, which includes the development, manufacture and marketing of radiopharmaceuticals and contrast products; Pharmaceutical Products, which includes the development, manufacture and distribution of dosage pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, which includes the development, manufacture and sale of nursing care products, medical surgical products and original equipment manufacturer products (OEM). The Company's customers include hospitals, surgi-centers, alternate site facilities, including long-term care facilities and imaging centers, drug manufacturers and retailers throughout the world. Its energy devices include its vessel sealing products, electrosurgical products, ablation products and related capital equipment. The Company's oximetry and monitoring products include its sensors and monitors products and its temperature management products. Its airway and ventilation products include its airway products, ventilator products, breathing systems, sleep products and inhalation therapy products. The Company offers a line of products used to monitor, diagnose and treat respiratory disease and sleep disorders. Through its Nellcor brand, the Company established pulse oximetry, which measures oxygen in the blood Imaging Solutions segment develops, manufactures and markets products, such as radiopharmaceuticals, which includes radioactive isotopes and associated pharmaceutical products used for the diagnosis and treatment of disease, and contrast products, which includes contrast delivery systems and contrast agents. The Pharmaceutical Products segment develops, manufactures and distributes the products, such as dosage pharmaceuticals, active pharmaceutical ingredients (API). The Medical Supplies segment develops, manufactures and distributes the products, su
» More Articles for NYSE:COV

Headlines

Articles On GuruFocus.com
A Strong Candidate for Investor´s Portfolios Aug 12 2014 
The Gabelli Equity Income Fund Second Quarter 2014 Shareholder Commentary Jul 25 2014 
Steven Romick's Top Five Stocks Jul 11 2014 
American Water Works - Nice Steady Upward Jun 21 2014 
Major British Companies Lead Top Guru-Held UK and Ireland Stocks Jun 10 2014 
4 Top Stocks in the Medical Device Sector Apr 11 2014 
Weekly Insider Sells Highlight: CUK, CBI, COV, DWRE Mar 30 2014 
Weekly CFO Sells Highlight: Chicago Bridge and Iron Company, Covidien PLC, Carnival PLC, Google Inc. Mar 30 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Can Malllinckrodt Keep on Crushing Expectations? Mar 19 2014 


Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK